Psychedelic Bulletin
Your weekly update on the psychedelics space. Connect the dots in this fast-paced ecosystem with exclusive insights, analysis, and expert comment.
Psychedelic Bulletin #125: New Data Boosts Spravato’s Case; Bipartisan Breakthrough Therapies Act; Berkeley Could Decrim. Psychedelics; DEA Increases Production Quotas
This week: New Phase 3b data boosts Spravato amid payer hesitancy; Berkeley Health Commission votes to move psychedelics decrim. resolution to City Council; our analysis of the rescheduling clauses in the Breakthrough Therapies Act; and much more…
Psychedelic Bulletin #124: MAPS Wraps Second Phase 3 MDMA Trial; Preparing for atai’s PCN-101 Results; Tactogen Launches Community Funding Round
This week: MAPS PBC finished its second Phase 3 trial of MDMA-AT for PTSD; we contextualise atai’s upcoming PCN-101 (R-Ketamine) readout; Tactogen launches crowdfunding round; and much more…
Psychedelic Bulletin #123: Colorado Psilocybin Therapy Prop Passes While Swathes of Oregon Opt-out; Sensorium Closes $30m Series A
This week: Colorado’s Prop 122 passes, decriminalising a number of psychedelics and establishing regulated psilocybin therapy; many Oregon counties opt-out; Sensorium closes $30m Series A round; and much more…
Psychedelic Bulletin #122: Lusaris Raises $60m to Develop 5-MeO-DMT; First Take-Home Psilocybin Trial in N. America; COMPASS Phase 2b Published in NEJM
This week: we take a look at the newest 5-MeO-DMT company to emerge; COMPASS’ Phase 2b psilocybin trial published in NEJM; Apex Labs set to trial take-home psilocybin; and much more…
Psychedelic Bulletin #121: The State of Psychedelic Economy and Industry; Dispatch from Horizons New York 2022
This week: Our preliminary dispatch from Horizons New York 2022; a write-up of a presentation on the state of psychedelic economy and industry; company news; and more…
Psychedelic Bulletin #120: Beckley Psytech Acquires Eleusis; A Look at COMPASS’ Phase 3 Design; New Psychedelic Drug Dev Scoops $22m Series A
This week: we take a look at COMPASS Pathways’ Phase 3 program; our quick take reaction to Beckley Psytech’s acquisition of Eleusis; Empyrean Neuroscience exits stealth with a $22m Series A; and much more…